HRSA further delays effective date of final rule on 340B drug ceiling prices

AHA News Now

The Health Resources and Services Administration today delayed to May 22 the effective date of its final rule on 340B drug ceiling prices and civil monetary penalties for manufacturers, and invited comments on whether a delay to Oct. 1 would be more appropriate. The rule was set to take effect March 21... read more

Topic: Advocacy and Public Policy
Tags: 340B, Drug Pricing Program, regulation, drug prices

AHA Stat blog: Congress should protect the 340B program

AHA News Now

“Congress should preserve the 340B Drug Pricing Program and protect patients and communities,” writes AHA Executive Vice President Tom Nickels in an AHA Stat blog post. He notes, “Every day, we see stories about the exorbitant costs of prescription drugs and the serious challenges they pose for... read more

Topic: Advocacy and Public Policy
Tags: 340B, Drug Pricing Program, drug prices

HRSA proposed rule would establish dispute resolution process for 340B program

AHA News Now

The Health Resources and Services Administration today released a proposed rule that would implement an Affordable Care Act provision requiring a binding administrative dispute resolution process for 340B Drug Pricing Program participants who claim they have been overcharged for drugs purchased through... read more

Topic: Advocacy and Public Policy
Tags: 340B, Drug Pricing Program, regulation

Hospitals, not pharmaceutical manufacturers, are preserving and protecting the safety net

Blog

A group financed by the pharmaceutical industry is hosting a meeting today on the 340B Drug Pricing Program with the goal of “Preserving the True Safety Net.” But what the meeting really will be about is the pharmaceutical industry – with their skyrocketing prescription drug prices and huge profits –... read more

Topic: Access and Coverage
Tags: 340B, Drug Pricing Program, Community benefit, access, drug prices

Changing 340B is the wrong prescription for addressing skyrocketing pharmaceutical costs

Blog

The rapidly rising costs of prescription drugs is causing significant financial challenges for patients and their care providers.

Many groups, including the AHA, are evaluating options for addressing this important issue. However, one recent proposal, which is seriously misguided, would reduce a program... read more

Topic: Access and Coverage
Tags: 340B, Drug Pricing Program, access, price, drug prices

CMS issues final rule for Medicaid drug rebates, reimbursement

AHA News Now

The Centers for Medicare & Medicaid Services yesterday published its long-awaited final rule implementing Affordable Care Act changes to the Medicaid Drug Rebate Program and Medicaid reimbursement for covered outpatient drugs. According to CMS, the rule creates a regulatory definition for Average... read more

Topic: Advocacy and Public Policy
Tags: 340B, Drug Pricing Program, Medicaid, regulation

AHA critical of MedPAC's "misdirected" 340B payment proposal

AHA News

The AHA last week criticized as “misdirected” and a blow to patient care the Medicare Payment Assessment Commission’s (MedPAC) recommendation that Congress reduce Part B drug payment rates to hospitals participating in the 340B Drug Pricing Program.

At its Jan. 14 meeting, the commission voted 14 to 3 to... read more

Topic: Advocacy and Public Policy
Tags: 340B, Drug Pricing Program

Amid concerns of possible policy changes, hospitals brief Congress on 340B's benefits

AHA News

At an AHA-sponsored briefing Nov. 19 on Capitol Hill, hospital leaders urged Congress to protect the 340B Drug Pricing Program, and shared with congressional staff the benefits that the program brings to vulnerable patients.

“People within the communities that Trinity Health serves receive tremendous and... read more

Topics: Access and Coverage, Advocacy and Public Policy
Tags: 340B, Drug Pricing Program, access

Protect Patients. Preserve 340B.

Blog

More than 20 years ago, Congress created the 340B Drug Pricing Program to allow eligible hospitals and health systems to stretch limited resources and expand access to care for vulnerable patients. But despite a proven track record of increasing patient access to vital medical services and decreasing... read more

Topic: Access and Coverage
Tags: 340B, Drug Pricing Program, access, price, drug prices

AHA: Proposed 340B guidance would hurt hospitals' ability to serve patients

AHA News Now

The Health Resources and Services Administration’s proposed omnibus guidance for the 340B Drug Pricing Program would jeopardize hospitals’ ability to serve vulnerable populations, including low-income and uninsured individuals and patients receiving cancer treatments, AHA told the agency in ... read more

Topic: Advocacy and Public Policy
Tags: 340B, Drug Pricing Program, Medicaid, drug prices

Keyword Search

Date